<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01385683</url>
  </required_header>
  <id_info>
    <org_study_id>1008073</org_study_id>
    <secondary_id>2010-024047-33</secondary_id>
    <nct_id>NCT01385683</nct_id>
  </id_info>
  <brief_title>Investigation Drug-drug Interaction Between Dabigatran and Clarithromycin</brief_title>
  <acronym>IMAGINE</acronym>
  <official_title>Investigation Drug-drug Interaction Between Dabigatran and Clarithromycin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Groupe de Recherche sur la Thrombose</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dabigatran (Pradaxa Â®) is a new oral anticoagulant. It is used to prevent venous
      thromboembolism in orthopedic surgery and has recently demonstrated efficacy and safety at
      least as good as anticoagulants in the prevention of thromboembolism in atrial fibrillation
      and the treatment of venous thromboembolism. It is administered with fixed dose and does not
      require laboratory monitoring because of the low inter and intra individual pharmacokinetic
      (PK) and pharmacodynamics (PD) of dabigatran. However, the bioavailability of dabigatran is
      very low (6.5%) and is controlled by an efflux protein, P-GP. This molecule has a genetic
      polymorphism. The inhibition of this protein can cause a significant increase in intestinal
      absorption of dabigatran and expose patients to a risk of bleeding by overdose. Two major
      drug interactions have been identified : quinidine (cons-indication) and amiodarone
      (precautions). It is likely that other interactions exist and can be clinically significant
      in patients not selected such as testing. The development of tools to study the influence of
      P-GP on the PK and PD of dabigatran is therefore interesting. As the P-GP has a genetic
      polymorphism, the study of the latter is an important element in the detection of drug
      interactions. In this sense, clarithromycin, a potent inhibitor of P-GP is a good model to
      evaluate the primary mechanism of drug interaction of dabigatran and optimize the
      experimental design of studies to be conducted.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of dabigatran and its metabolites in plasma by LC/MS-MS method</measure>
    <time_frame>At Day 4 and Day 11</time_frame>
    <description>Calculating the area under the curve (AUC) from plasma concentrations of dabigatran versus time by the trapezoidal method. Determination of maximum concentration (Cmax)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic parameters</measure>
    <time_frame>At Day 4 and Day 11</time_frame>
    <description>Measures activated Partial Thromboplastin Time (aPTT)and measures ECarin Time (ECT),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotyping</measure>
    <time_frame>At Day 1</time_frame>
    <description>Genotyping of MDR-1 (gene for P-GP): C3435T SNP of exon 26, SNP G2677T / A of exon 21 and C1236T SNP of exon 12</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dabigatran then dabigatran and clarithromycin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clarithromycin and dabigatran and dabigatran</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran then dabigatran and clarithromycin</intervention_name>
    <description>D4 : dabigatran 300 mg (4 tablets) one time. D8 to D10 : Clarithromycin 500mg (1 tablet) twice daily. D11 : Clarithromycin 500mg (1 tablet) + 300mg dabigatran (4 tablets)</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Dabigatran (Pradaxa)75 mg</other_name>
    <other_name>Clarithromycin (Zeclar) 500 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin and dabigatran then dabigatran</intervention_name>
    <description>D1 to D3 : Clarithromycin 500mg (1 tablet) twice daily. D4 : Clarithromycin 500mg (1 tablet) + 300mg dabigatran (4 tablets). D11 : dabigatran 300 mg (4 tablets) one time.</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Dabigatran (Pradaxa) 75 mg</other_name>
    <other_name>Clarithromycin (Zeclar) 500 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  affiliated or beneficiary of a social security category

          -  having signed the inform consent form

          -  having signed the genetic consent form

          -  weight between 60 and 85 kg

          -  normal clinical exam

          -  normal biological exam

        Exclusion Criteria:

          -  contra-indication to dabigatran

          -  contra-indication to clarithromycin

          -  previous history of psychiatric disease, or antidepressant treatment, or convulsion,
             or hemorrhagic disease

          -  smoker

          -  peptic ulcer

          -  severe liver disease

          -  severe kidney failure

          -  previous surgery within one month
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick MISMETTI, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Saint-Etienne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xavier DELAVENNE, Pharmacist</last_name>
    <role>Study Chair</role>
    <affiliation>CHU de Saint-Etienne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de Medecine et Therapeutique</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2011</study_first_submitted>
  <study_first_submitted_qc>June 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2011</study_first_posted>
  <last_update_submitted>March 21, 2012</last_update_submitted>
  <last_update_submitted_qc>March 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteer</keyword>
  <keyword>Pharmacokinetic</keyword>
  <keyword>pharmacodynamic</keyword>
  <keyword>Polymorphism, Genetic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

